Welcome to our dedicated page for IBEX SEC filings (Ticker: IBEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IBEX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IBEX's regulatory disclosures and financial reporting.
Dechant Robert Thomas reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd reported that Chief Executive Officer Robert Thomas Dechant received an award of 18,000 Common Share–settled restricted stock units. These RSUs were granted at no cash cost and increase his directly held stake to 293,406 Common Shares, aligning his compensation further with shareholder interests.
According to the grant terms, 25% of the RSUs vest on July 1, 2026, with additional 25% installments vesting annually over the following three years, as long as he remains in continuous service. On each vesting date, IBEX will automatically withhold a portion of the resulting shares to cover tax withholding obligations in a non-discretionary transaction.
Greenwald Taylor C reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd Chief Financial Officer Taylor C. Greenwald received a grant of 5,500 restricted stock units tied to IBEX common shares. Each RSU represents the right to receive one share. 25% vest on July 1, 2026, with additional 25% tranches vesting annually over the following three years, contingent on continued service. On each vesting date, IBEX will automatically withhold shares to cover tax obligations.
IBEX Ltd reported that Chief Operating Officer David Martin Afdahl acquired 4,400 common shares through a grant of restricted stock units. These RSUs carry no purchase price and represent a right to receive one share of common stock for each unit as they vest.
According to the award terms, 25% of the RSUs vest on July 1, 2026, with an additional 25% vesting each year for the next three years, as long as he remains in continuous service on each vesting date. Shares of common stock will be automatically withheld at each vesting to cover tax obligations. After this grant, he directly holds 157,302 common shares.
IBEX Ltd reported that Chief Sales/Marketing Officer Julie K. Casteel acquired 4,400 restricted stock units (RSUs) representing common shares. Each RSU converts into one common share as it vests. After this grant, she holds 121,194 common shares directly.
According to the award terms, 25% of the RSUs vest on July 1, 2026, with an additional 25% vesting on the same date in each of the following three years, provided she remains in continuous service. On each vesting date, shares of common stock will be automatically withheld to cover tax withholding obligations in a non‑discretionary transaction.
IBEX Ltd reported that Chief Sales and CS Officer Bruce Neil Dawson acquired 3,250 common shares through a grant of restricted stock units (RSUs) at a stated price of $0.00 per share. These RSUs convert into one common share each as they vest over time.
According to the award terms, 25% of the RSUs vest on July 1, 2026, with an additional 25% vesting annually over the following three years, so long as he remains continuously employed on each vesting date. After this grant, he directly holds 80,284 common shares. On each vesting date, a portion of shares will automatically be withheld by IBEX to cover tax withholding obligations in a non-discretionary transaction.
IBEX Ltd reported an equity award to its Chief Legal Officer, Christina Alice Trofimuk-O'Connor. She acquired 4,400 common shares in the form of restricted stock units (RSUs) at a price of $0.0000 per share, bringing her direct holdings to 35,735 common shares.
The RSUs vest over four years: 25% on July 1, 2026, with 25% vesting each year for the following three years, contingent on continued service. On each vesting date, IBEX will automatically withhold shares to cover tax obligations in a non-discretionary transaction.
Inson Paul Joseph reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd reported that Chief People Officer Paul Joseph Inson received a grant of 4,000 restricted stock units, each representing a right to one common share. The RSUs vest 25% on July 1, 2026, then 25% annually over the next three years, subject to continued service. After this award, he holds 31,469 common shares directly. On each vesting date, a portion of shares will be automatically withheld to cover tax obligations.
IBEX Ltd insider Michael Joseph Darwal, the Chief AI & Digital Officer, reported an "other" type transaction involving 925 Common Shares at a reference price of $28.39 per share. After this event, his directly held stake is 41,260 Common Shares.
According to the footnote, these shares were transferred to a third party under a legal agreement related to a divorce dated December 29, 2025. The filing states that this transfer does not represent a discretionary transaction by the reporting person, indicating it was driven by personal legal obligations rather than an active investment decision.
IBEX Ltd director and Chief Executive Officer Robert Thomas Dechant reported an open-market sale of 6,000 Common Shares. The shares were sold at a weighted average price of $28.4588 per share in multiple trades. After this transaction, he directly owns 275,406 Common Shares.
The sale price reflects a weighted average of individual trades executed between $28.25 and $29.02 per share, and detailed trade breakdowns are available upon request as noted in the filing footnote.
IBEX Ltd. registered proposed sales of common stock by a reporting person through RBC Capital Markets LLC. The filing lists four proposed sale entries of 6,000 shares each on 02/17/2026, 02/18/2026, 02/19/2026, and 02/20/2026.
The entries show dollar figures for each trade on those dates; the filing is a routine Form 144 notice of intended sales under broker arrangement.